Barriers to medication adherence and its relationship with outcomes in pediatric dialysis patients

Douglas M Silverstein1, Angela Fletcher, Kathleen Moylan

  • 1Office of Device Evaluation, Renal Devices Branch (RNDB), United States Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20903, USA, dsilverstein2001@yahoo.com.

Insights

Medication adherence challenges exist for pediatric dialysis patients. Difficulties were more pronounced in peritoneal dialysis (PD) patients compared to hemodialysis (HD) patients, indicating a need for targeted support.

Area of Science:

  • Pediatric Nephrology
  • Chronic Disease Management
  • Renal Replacement Therapy

Background:

  • Medication adherence is critical for pediatric chronic disease outcomes.
  • Children with end-stage renal disease face complex medication regimens alongside renal replacement therapy.

Purpose of the Study:

  • To assess barriers to medication adherence in pediatric patients undergoing chronic dialysis.
  • To compare adherence challenges between hemodialysis (HD) and peritoneal dialysis (PD) modalities.

Main Methods:

  • A survey of 22 pediatric dialysis patients (63.6% HD, 36.4% PD) assessed medication adherence using a 16-question survey (max score 64).
  • Patient demographics including age and dialysis vintage were recorded.
  • Mineral bone disease markers and treatment targets were evaluated.

Main Results:

  • The overall mean adherence score was 30.9 (range 16-49).
  • Patients on peritoneal dialysis (PD) showed significantly higher mean scores per question (indicating greater difficulty) compared to hemodialysis (HD) patients (p=0.006).
  • No significant relationship was found between adherence scores and gender, age, dialysis vintage, or number of treatment targets reached.

Conclusions:

  • Pediatric dialysis patients encounter numerous barriers to medication adherence.
  • Medication adherence difficulties were more apparent in patients receiving peritoneal dialysis (PD) than hemodialysis (HD).
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408
Peritoneal Dialysis III: Nursing Management01:25

Peritoneal Dialysis III: Nursing Management

Peritoneal dialysis, or PD, utilizes the peritoneal membrane as a filter to eliminate excess fluid and waste products. Effective nursing management is essential for ensuring patient safety, preventing complications, and promoting optimal function of the peritoneal dialysis process.Assessment and MonitoringNurses must thoroughly assess the patient before, during, and after each dialysis session. Regular monitoring includes vital signs, daily weight, fluid intake and output, and laboratory values...
1.6K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410